stockrow
Friday 6 November 2026
Export BWAY’s income statement to Excel — free account
Brainsway Ltd. Sponsored ADR
BWAY Healthcare Medical Devices
Brainsway Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $52.2 million, up 27.3% from fiscal 2024.
- Revenue
- +35.4%
- EPS
- +40.0%
- Free cash flow
- −51.7%
Quarter to June 2026, against a year earlier
11.14
0.53
+5.00%
Follow BWAY
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
47.09 | 23.78 | 28.89 | 31.02 |
P/S ratio |
6.01 | 3.46 | 4.51 | 4.95 | |
P/FCF ratio |
16.08 | 11.93 | 21.90 | 51.89 | |
P/Operating CF |
212.84 | (139.98) | 216.58 | 47.62 | |
P/B ratio |
4.21 | 2.47 | 3.35 | 3.79 | |
Price to Tangible BV |
4.21 | 2.47 | 3.35 | 3.79 | |
EV/Sales |
4.60 | 2.19 | 3.49 | 3.95 | |
EV/EBITDA |
47.77 | 19.48 | 26.69 | 25.97 | |
EV/Operating CF |
10.15 | 6.53 | 14.39 | 31.66 | |
EV/FCF |
12.33 | 7.54 | 16.96 | 41.42 | |
Quick Ratio |
2.96 | 3.27 | 2.87 | 3.11 | |
Current Ratio |
3.19 | 3.73 | 3.34 | 3.59 | |
Net Debt/EBITDA |
(43.32) | (30.59) | (24.30) | (22.39) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.53 | 0.50 | 0.52 | 0.52 | |
Operating CF/Net income |
0.89 | (0.45) | 0.51 | 2.33 | |
Capex/Depreciation |
(1.98) | 1.90 | (1.65) | (2.00) | |
Interest Coverage |
2.19 | 7.15 | 6.29 | 2.72 | |
Research and Development Expense of Revenue |
17.73% | 17.40% | 18.55% | 18.82% | |
Selling, General and Administrative Expense of Revenue |
48.18% | 45.86% | 43.71% | 41.83% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
2.69% | 1.93% | 2.20% | 3.89% | |
Graham Net Nets |
0.14 | 0.24 | 0.15 | 0.13 | |
Graham Number |
5.08 | 5.89 | 6.41 | 6.78 | |
Earnings Yield |
2.12% | 4.21% | 3.46% | 3.22% | |
Free Cash Flow Yield |
6.22% | 8.38% | 4.57% | 1.93% | |
Revenue per Share |
0.69 | 0.77 | 0.81 | 0.88 | |
Operating CF per Share |
0.07 | (0.07) | 0.06 | 0.33 | |
Capex per Share |
(0.04) | 0.04 | (0.04) | (0.05) | |
Free Cash Flow per Share |
0.03 | (0.03) | 0.02 | 0.28 | |
Cash per Share |
3.67 | 3.65 | 3.15 | 3.28 | |
Shareholders Equity per Share |
3.58 | 3.85 | 3.97 | 4.09 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.58 | 3.85 | 3.97 | 4.09 | |
Free Cash Flow |
0.59 | (0.62) | 0.40 | 5.42 | |
Working Capital |
56.94 | 61.33 | 55.07 | 58.75 | |
Capital Expenditures |
(0.80) | 0.67 | (0.77) | (0.88) | |
Net Current Asset Value |
39.94 | 43.80 | 37.43 | 38.64 | |
EV/EBIT |
79.66 | 26.42 | 34.15 | 31.68 | |
Capex to Sales |
0.06 | (0.05) | 0.05 | 0.05 | |
Price to Operating Income |
103.94 | 41.80 | 44.09 | 39.69 | |
| Other line items | |||||
Average Receivables |
4.33 | 4.35 | 7.24 | 5.45 | |
Average Payables |
2.03 | 2.65 | 2.52 | 1.86 | |
Average Inventory |
4.05 | 5.47 | 5.88 | 5.75 | |
Average Assets |
92.58 | 103.75 | 108.60 | 116.77 | |
Average Common Equity |
57.05 | 67.74 | 69.77 | 73.66 |
Columns are period end dates · fundamentals updated 26 Oct 2026